Megan E. Tesch, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X about a paper she and Ann Partridge co-authored published in Journal of Clinical Oncology:
“Premature discontinuation of adjuvant Endocrine Therapy is common in early breast cancer – Ann Partridge and I discuss the study by Dumas et al. modelling the potential survival benefits of improved ET persistence, particularly for young adults with breast cancer.”
Title: Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes for Patients With Early-Stage Breast Cancer?
Authors: Megan E. Tesch and Ann Partridge
Read the Full Article on Journal of Clinical Oncology.
More posts featuring Megan E. Tesch.